Floatz logo

Vinorelbine

Recurrent Breast Carcinoma

Fudan UniversityPhase 3Active
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
64/ 100
Competitive Position
89/ 100

Competitive context

25 Active assets in the Recurrent Breast Carcinoma cohort.

Asset / SponsorPhaseRating
TAMOXIFEN
Xijing Hospital
Phase 4BBB
Epirubicin
UNC Lineberger Comprehensive Cancer Center
Phase 3BBB
Olaparib
The Netherlands Cancer Institute
Phase 4BBB
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Institute (NCI)
Phase 3BB
Temsirolimus
M.D. Anderson Cancer Center
Phase 2BB

View all 50 →

Same molecule, other indications

Vinorelbine is also rated in:

HER2 positive breast carcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
cervical cancerDormant
BBB
Indicative ·
72 / 100
View asset →
Hodgkins lymphomaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →